Ocugen Q3 revenue beats expectations, net loss narrows

By Reuters News


Overview

  • US gene therapy developer's Q3 revenue rose and beat analyst expectations

  • Net loss per share for Q3 narrowed to $0.01 from $0.07 last year

  • Company received provisional approval for OCU400 in The Bahamas and signed MENA licensing deal


Outlook

  • Company expects OCU400 Phase 3 topline data in Q1 2027, with BLA submission to follow

  • OCU410ST Phase 2/3 topline data anticipated in Q2 2027, with BLA submission planned

  • Company expects cash runway to extend into 2028


Result Drivers

  • OPERATING EXPENSES - Q3 operating expenses rose slightly due to higher research and development spending, partially offset by lower general and administrative costs


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$1.95 mln

$1.10 mln (6 Analysts)

Q3 Loss Per Share

$0.01

Q3 Net Loss

$3.60 mln

Q3 Operating Expenses

$19.70 mln

Q3 Profit From Operations

-$17.75 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Ocugen, Inc. is $10.50, about 1,309% above its November 3 closing price of $0.75


Reuters Recommended Reads

  • Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027

  • Nov 2 - Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially

  • Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk